# Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL

> **NCT06879262** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 60 (estimated)

## Conditions studied

- R/R NHL

## Interventions

- **BIOLOGICAL:** CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）

## Key facts

- **NCT ID:** NCT06879262
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-15
- **Primary completion:** 2028-02-28
- **Final completion:** 2029-02-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06879262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06879262, "Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06879262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*